Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

NCT06027268 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Triple-Negative Breast Cancer

Interventions

DRUG: Trilaciclib
DRUG: Pembrolizumab
DRUG: Gemcitabine
DRUG: Carboplatin

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]
[object Object]